JP2015503590A5 - - Google Patents

Download PDF

Info

Publication number: JP2015503590A5
Authority: JP; Japan
Prior art keywords: amount; pharmaceutical composition; composition; epa; plasma
Prior art date: 2013-01-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2014551376A

Other languages

English (en)

Japanese (ja)

Other versions

JP6399655B2 (ja

JP2015503590A (ja

Filing date

2013-01-04

Publication date

2016-03-17

2013-01-04 Application filed filed Critical

2013-01-04 Priority claimed from PCT/US2013/020398 external-priority patent/WO2013103902A1/en

2015-02-02 Publication of JP2015503590A publication Critical patent/JP2015503590A/ja

2016-03-17 Publication of JP2015503590A5 publication Critical patent/JP2015503590A5/ja

2018-10-03 Application granted granted Critical

2018-10-03 Publication of JP6399655B2 publication Critical patent/JP6399655B2/ja

Status Expired - Fee Related legal-status Critical Current

2033-01-04 Anticipated expiration legal-status Critical

Links

239000008194 pharmaceutical composition Substances 0.000 claims description 65
238000000034 method Methods 0.000 claims description 42
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 32
239000002552 dosage form Substances 0.000 claims description 26
210000002966 serum Anatomy 0.000 claims description 18
235000021342 arachidonic acid Nutrition 0.000 claims description 16
229940114079 arachidonic acid Drugs 0.000 claims description 16
239000002253 acid Substances 0.000 claims description 14
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 12
239000004202 carbamide Substances 0.000 claims description 12
239000002775 capsule Substances 0.000 claims description 10
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 9
239000007903 gelatin capsule Substances 0.000 claims description 8
239000002994 raw material Substances 0.000 claims description 8
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 8
230000009918 complex formation Effects 0.000 claims description 6
150000003626 triacylglycerols Chemical class 0.000 claims description 6
101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 claims description 3
101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 claims description 3
208000006575 hypertriglyceridemia Diseases 0.000 claims description 3
235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 3
238000002203 pretreatment Methods 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 3
FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims description 2
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 2
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 2
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 2
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 2
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 2
229960005370 atorvastatin Drugs 0.000 claims description 2
125000004494 ethyl ester group Chemical group 0.000 claims description 2
235000021323 fish oil Nutrition 0.000 claims description 2
229960003765 fluvastatin Drugs 0.000 claims description 2
229960004844 lovastatin Drugs 0.000 claims description 2
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 2
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
229960002797 pitavastatin Drugs 0.000 claims description 2
VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 2
229960002965 pravastatin Drugs 0.000 claims description 2
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 2
229960000672 rosuvastatin Drugs 0.000 claims description 2
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 2
229960002855 simvastatin Drugs 0.000 claims description 2
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 2
239000000203 mixture Substances 0.000 claims 15
108010010803 Gelatin Proteins 0.000 description 8
229920000159 gelatin Polymers 0.000 description 8
239000008273 gelatin Substances 0.000 description 8
235000019322 gelatine Nutrition 0.000 description 8
235000011852 gelatine desserts Nutrition 0.000 description 8
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
230000037406 food intake Effects 0.000 description 2
HTEAGOMAXMOFFS-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.COC(=O)C(C)=C HTEAGOMAXMOFFS-UHFFFAOYSA-N 0.000 description 2
229920003163 Eudragit® NE 30 D Polymers 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
235000020660 omega-3 fatty acid Nutrition 0.000 description 1
235000020665 omega-6 fatty acid Nutrition 0.000 description 1
239000008213 purified water Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

JP2014551376A 2012-01-06 2013-01-04 遊離酸型のオメガ−３多価不飽和脂肪酸のｄｐａ濃縮組成物 Expired - Fee Related JP6399655B2 (ja)

Applications Claiming Priority (13)

Application Number	Priority Date	Filing Date	Title
US201261583796P	2012-01-06	2012-01-06
US61/583,796		2012-01-06
US201261664047P	2012-06-25	2012-06-25
US61/664,047		2012-06-25
US201261669940P	2012-07-10	2012-07-10
US61/669,940		2012-07-10
US201261680622P	2012-08-07	2012-08-07
US61/680,622		2012-08-07
US201261710517P	2012-10-05	2012-10-05
US61/710,517		2012-10-05
US201261713388P	2012-10-12	2012-10-12
US61/713,388		2012-10-12
PCT/US2013/020398 WO2013103902A1 (en)	2012-01-06	2013-01-04	Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2017123521A Division JP6626857B2 (ja)	2012-01-06	2017-06-23	遊離酸型のオメガ−３多価不飽和脂肪酸のｄｐａ濃縮組成物

Publications (3)

Publication Number	Publication Date
JP2015503590A JP2015503590A (ja)	2015-02-02
JP2015503590A5 true JP2015503590A5 (2)	2016-03-17
JP6399655B2 JP6399655B2 (ja)	2018-10-03

Family

ID=48744082

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2014551376A Expired - Fee Related JP6399655B2 (ja)	2012-01-06	2013-01-04	遊離酸型のオメガ−３多価不飽和脂肪酸のｄｐａ濃縮組成物
JP2017123521A Expired - Fee Related JP6626857B2 (ja)	2012-01-06	2017-06-23	遊離酸型のオメガ−３多価不飽和脂肪酸のｄｐａ濃縮組成物
JP2019217081A Ceased JP2020045358A (ja)	2012-01-06	2019-11-29	遊離酸型のオメガ−３多価不飽和脂肪酸のｄｐａ濃縮組成物

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
JP2017123521A Expired - Fee Related JP6626857B2 (ja)	2012-01-06	2017-06-23	遊離酸型のオメガ−３多価不飽和脂肪酸のｄｐａ濃縮組成物
JP2019217081A Ceased JP2020045358A (ja)	2012-01-06	2019-11-29	遊離酸型のオメガ−３多価不飽和脂肪酸のｄｐａ濃縮組成物

Country Status (35)

Country	Link
US (5)	US20150004224A1 (2)
EP (2)	EP3348262A1 (2)
JP (3)	JP6399655B2 (2)
KR (2)	KR102153143B1 (2)
CN (3)	CN104321055A (2)
BR (1)	BR112014016788A8 (2)
CA (1)	CA2860512C (2)
CL (1)	CL2014001803A1 (2)
CO (1)	CO7061070A2 (2)
CY (1)	CY1120663T1 (2)
DK (1)	DK2800563T3 (2)
DO (1)	DOP2014000159A (2)
EC (1)	ECSP14012527A (2)
ES (1)	ES2685703T3 (2)
HK (1)	HK1251457A1 (2)
HR (1)	HRP20181418T1 (2)
HU (1)	HUE039659T2 (2)
IL (3)	IL233517A (2)
IN (1)	IN2014DN06125A (2)
LT (1)	LT2800563T (2)
MX (1)	MX358319B (2)
MY (1)	MY165048A (2)
NZ (1)	NZ626699A (2)
PE (1)	PE20142459A1 (2)
PH (2)	PH12014501553A1 (2)
PL (1)	PL2800563T3 (2)
PT (1)	PT2800563T (2)
RS (1)	RS57777B1 (2)
RU (2)	RU2018116572A (2)
SG (2)	SG10201701004RA (2)
SI (1)	SI2800563T1 (2)
SM (1)	SMT201800519T1 (2)
UA (1)	UA114615C2 (2)
WO (1)	WO2013103902A1 (2)
ZA (1)	ZA201405765B (2)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0907413D0 (en)	2009-04-29	2009-06-10	Equateq Ltd	Novel methods
RS57777B1 (sr) *	2012-01-06	2018-12-31	Omthera Pharmaceuticals Inc	Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
EP2846779A4 (en)	2012-05-07	2015-12-16	Omthera Pharmaceuticals Inc	STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS
EP2861227A4 (en)	2012-06-17	2016-01-27	Matinas Biopharma Inc	OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
GB201216385D0 (en) *	2012-09-13	2012-10-31	Chrysalis Pharma Ag	A pharmaceutical composition
KR20150098611A (ko) *	2012-10-23	2015-08-28	디킨 유니버시티	트리글리세라이드를 감소시키기 위한 방법
US9629820B2 (en)	2012-12-24	2017-04-25	Qualitas Health, Ltd.	Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en)	2012-12-24	2018-11-13	Qualitas Health, Ltd.	Eicosapentaenoic acid (EPA) formulations
GB201301626D0 (en)	2013-01-30	2013-03-13	Dignity Sciences Ltd	Composition comprising 15-OHEPA and methods of using the same
US9452151B2 (en) *	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
WO2015011724A2 (en)	2013-07-22	2015-01-29	Kms Health Center Pvt Ltd	A novel omega -3 fatty acid composition with a plant extract
WO2015024055A1 (en) *	2013-08-20	2015-02-26	Deakin University	Separation of omega-3 fatty acids
CA2926335C (en)	2013-10-30	2021-11-23	Banner Life Sciences Llc	Enteric soft capsules comprising polyunsaturated fatty acids
JP2016538288A (ja)	2013-11-15	2016-12-08	ディグニティサイエンシスリミテッド	多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
CA2947741A1 (en)	2014-05-05	2015-11-12	Thetis Pharmaceuticals Llc	Compositions and methods relating to ionic salts of peptides
US9682055B2 (en) *	2014-06-04	2017-06-20	Dignity Sciences Limted	Pharmaceutical compositions comprising DGLA and use of same
US9242008B2 (en)	2014-06-18	2016-01-26	Thetis Pharmaceuticals Llc	Mineral amino-acid complexes of fatty acids
US9999626B2 (en)	2014-06-18	2018-06-19	Thetis Pharmaceuticals Llc	Mineral amino-acid complexes of active agents
US9895333B2 (en)	2014-06-26	2018-02-20	Patheon Softgels Inc.	Enhanced bioavailability of polyunsaturated fatty acids
WO2016069446A1 (en) *	2014-10-28	2016-05-06	Omthera Pharmaceuticals Inc	Methods for modulating plasma levels of lipoproteins
WO2016073335A1 (en) *	2014-11-05	2016-05-12	Omthera Pharmaceuticals Inc.	Methods of treatment
US20160192126A1 (en) *	2014-12-31	2016-06-30	Silver Spring Networks, Inc.	System and method for tracking a device
MA41611A (fr) *	2015-02-23	2018-01-02	Omthera Pharmaceuticals Inc	Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
WO2016178066A1 (en) *	2015-05-01	2016-11-10	Mohan M Alapati	Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
MA47141A (fr)	2015-05-13	2019-11-06	Ds Biopharma Ltd	Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
ES2851525T3 (es)	2015-07-21	2021-09-07	Afimmune Ltd	Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
CA3129008A1 (en)	2015-12-18	2017-06-22	Afimmune Limited	Compositions comprising 15-hepe and methods of using the same
US10263794B2 (en) *	2016-05-19	2019-04-16	Linear Technology Corporation	Maintain power signature controller at power interface of PoE or PoDL system
ES2827796T3 (es)	2016-06-03	2021-05-24	Thetis Pharmaceuticals Llc	Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
GB201611920D0 (en)	2016-07-08	2016-08-24	Astrazeneca Ab	Pharmaceutical compositions
MX2019013683A (es)	2017-05-16	2020-01-15	Ability Pharmaceuticals Sl	Una combinacion farmaceutica para el tratamiento de un cancer.
EP3648748A1 (en)	2017-07-06	2020-05-13	Evonik Operations GmbH	Enteric coated solid dosage form comprising omega-3 fatty acid amino acid salts
JP7050148B2 (ja)	2017-08-15	2022-04-07	エボニックオペレーションズゲーエムベーハー	オメガ－３脂肪酸アミノ酸塩の有効成分含有量が高い錠剤
EP3586640A1 (en)	2018-06-21	2020-01-01	Nuseed Pty Ltd	Dha enriched polyunsaturated fatty acid compositions
EP3586642A1 (en)	2018-06-21	2020-01-01	Nuseed Pty Ltd	Ala enriched polyunsaturated fatty acid compositions
EP3586641A1 (en)	2018-06-21	2020-01-01	Nuseed Pty Ltd	Dha enriched polyunsaturated fatty acid compositions
EP3586643A1 (en)	2018-06-21	2020-01-01	Nuseed Pty Ltd	Dha enriched polyunsaturated fatty acid compositions
EP4009961A1 (en)	2019-08-08	2022-06-15	Evonik Operations GmbH	Solubility enhancement of poorly soluble actives
US20220280387A1 (en)	2019-08-08	2022-09-08	Evonik Operations Gmbh	Down streaming process for the production of polyunsaturated fatty acid salts
US20210315851A1 (en)	2020-04-03	2021-10-14	Afimmune Limited	Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5735512A (en)	1980-06-27	1982-02-26	Nippon Oil & Fats Co Ltd	Preventive and remedy for thrombosis
US4377526A (en)	1981-05-15	1983-03-22	Nippon Suisan Kaisha, Ltd.	Method of purifying eicosapentaenoic acid and its esters
BR8803255A (pt)	1981-11-10	1990-02-06	Century Lab Inc	Processo de extracao e purificacao de acidos graxos poli-insaturados de fontes naturais
JPS59157018A (ja)	1983-02-27	1984-09-06	Furointo Sangyo Kk	新規なる被覆含油カプセル剤形
JPS59225115A (ja)	1983-06-06	1984-12-18	Ota Seiyaku Kk	青魚類から得た長鎖高度不飽和脂肪酸を含有する微細カプセル
JPS61126016A (ja)	1984-11-22	1986-06-13	Toagosei Chem Ind Co Ltd	不飽和脂肪酸を内相物としたマイクロカプセル
EP0347509A1 (en)	1988-06-21	1989-12-27	Century Laboratories Inc.	A process of extraction and purification of polyunsaturated fatty acids from natural sources
CH669208A5 (fr)	1986-12-17	1989-02-28	Nestle Sa	Procede de fractionnement en continu d'un melange d'acides gras.
US5243046A (en)	1986-12-17	1993-09-07	Nestec S.A.	Process for the continuous fractionation of a mixture of fatty acids
EP0289204B1 (en)	1987-04-27	1991-07-17	Efamol Holdings Plc	Lithium salt-containing pharmaceutical compositions
IT1205043B (it)	1987-05-28	1989-03-10	Innova Di Ridolfi Flora & C S	Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
US4843095A (en)	1987-08-07	1989-06-27	Century Laboratories, Inc.	Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
ZA885473B (en)	1987-08-07	1989-03-29	Century Lab Inc	Free fatty acids for treatment of diabetes mellitus
GB8819110D0 (en)	1988-08-11	1988-09-14	Norsk Hydro As	Antihypertensive drug & method for production
GB2223943A (en)	1988-10-21	1990-04-25	Tillotts Pharma Ag	Oral disage forms of omega-3 polyunsaturated acids
NL9201438A (nl)	1992-08-11	1994-03-01	Prospa Bv	Nieuwe farmaceutische samenstellingen die esters van omega-3 polyonverzadigde zuren omvatten en de toepassing ervan bij de plaatselijke behandeling van ziekelijke aandoeningen.
CA2151820C (en)	1993-01-15	2000-11-28	Stephen Joseph Demichele	Structured lipids
US5719302A (en)	1993-04-29	1998-02-17	Pronova A.S	Processes for chromatographic fractionation of fatty acids and their derivatives
JPH0753356A (ja)	1993-08-16	1995-02-28	Morishita Jintan Kk	酸化され易い油性物質を内容物とするシームレスカプセルおよびその製造方法
US5767156A (en)	1993-10-06	1998-06-16	Peptide Technology Limited	Polyunsaturated fatty acids and uses thereof
IT1264987B1 (it)	1993-12-14	1996-10-17	Prospa Bv	Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
US5494684A (en)	1994-02-23	1996-02-27	Bar-Ilan University	Plant protection from infection by Phytophthora infestans using fish oil
GB9404483D0 (en)	1994-03-08	1994-04-20	Norsk Hydro As	Refining marine oil compositions
RU2127115C1 (ru)	1994-03-28	1999-03-10	Владимир Константинович Гаврисюк	Смесь омега-3 полиненасыщенных жирных кислот
DK0682006T3 (da)	1994-05-09	1999-10-18	Nestle Sa	Fremgangsmåde til fremstilling af et koncentrat af estere af flerumættede fede syrer
IT1274734B (it)	1994-08-25	1997-07-24	Prospa Bv	Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
JPH08100191A (ja) *	1994-09-30	1996-04-16	Nisshin Flour Milling Co Ltd	高度不飽和脂肪酸またはそのエステルの精製方法
NL9401743A (nl)	1994-10-20	1996-06-03	Prospa Bv	Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten.
GB2300807B (en)	1995-05-15	1999-08-18	Tillotts Pharma Ag	Oral dosage forms of omega-3 polynunsaturated acids for the treatment of inflammatory bowel disease
GB9509764D0 (en)	1995-05-15	1995-07-05	Tillotts Pharma Ag	Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
AU2738497A (en)	1996-04-24	1997-11-12	Brigham And Women's Hospital	Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6077828A (en)	1996-04-25	2000-06-20	Abbott Laboratories	Method for the prevention and treatment of cachexia and anorexia
JPH1095744A (ja) *	1996-09-20	1998-04-14	Nof Corp	高度不飽和脂肪酸又はそのアルキルエステルの製造方法
EP0843972B1 (en) *	1996-11-20	2002-07-31	N.V. Nutricia	Nutritional composition comprising fats for the treatment of the metabolic syndrome
GB9701705D0 (en)	1997-01-28	1997-03-19	Norsk Hydro As	Purifying polyunsatured fatty acid glycerides
CA2281949A1 (en)	1997-02-25	1998-08-27	Genzyme Transgenics Corporation	Transgenically produced non-secreted proteins
US6852870B2 (en)	1999-03-22	2005-02-08	Andrew Stoll	Omega-3 fatty acids in the treatment of depression
WO1999029316A1 (en)	1997-12-10	1999-06-17	Severson, Mary, L.	Pharmaceutical compositions containing an omega-3 fatty acid oil
NO312973B1 (no)	1999-02-17	2002-07-22	Norsk Hydro As	Lipase-katalysert forestring av marine oljer
US7112609B2 (en)	1999-06-01	2006-09-26	Drugtech Corporation	Nutritional supplements
JP2001054396A (ja)	1999-06-08	2001-02-27	Nippon Suisan Kaisha Ltd	リパーゼによる高度不飽和脂肪酸含有油脂の製造方法
AU5319499A (en)	1999-07-22	2001-02-13	Ivan L. Cameron	Fatty acids to minimize cancer therapy side effects
NO310113B1 (no)	1999-08-11	2001-05-21	Norsk Hydro As	Fremgangsmåte for utvinning av flerumettede fettsyrer fra ureakomplekser
AU6813700A (en)	1999-08-30	2001-03-26	Ocean Nutrition Canada Ltd.	A nutritional supplement for lowering serum triglyceride and cholesterol levels
CN1179725C (zh)	1999-08-31	2004-12-15	中外制药株式会社	软胶囊剂
EP1106072B1 (en)	1999-12-10	2005-11-30	Loders Croklaan B.V.	Palmitoleic acid and its use in foods
WO2001049282A2 (en)	2000-01-06	2001-07-12	Martek Biosciences Corporation	Therapeutic preparations of highly unsaturated fatty acids
DK1157692T3 (da)	2000-05-22	2006-02-06	Pro Aparts Investimentos E Con	Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
GB0016045D0 (en)	2000-06-29	2000-08-23	Laxdale Limited	Therapeutic combinations of fatty acids
GB0016452D0 (en)	2000-07-04	2000-08-23	Kilgowan Limited	Vitamin K and essential fatty acids
EP1178103A1 (en)	2000-08-02	2002-02-06	Dsm N.V.	Purifying crude pufa oils
KR20010008387A (ko)	2000-11-30	2001-02-05	이성권	결정화방법을 이용한 고순도 불포화지방산의 분리 정제 방법
CN102319266B (zh)	2001-06-18	2014-12-17	海王星技术&生物资源有限公司	用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物
CN1197564C (zh) *	2001-09-30	2005-04-20	中国药品生物制品检定所	海狗油在制备治疗脂代谢紊乱药物中的应用
ITMI20012384A1 (it)	2001-11-12	2003-05-12	Quatex Nv	Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
GB2385852A (en)	2002-02-27	2003-09-03	Rothamsted Ex Station	Delta 6-desaturases from Primulaceae
AU2003218319A1 (en)	2002-03-22	2003-10-13	Doc's Guide, Inc.	Multivitamin and mineral nutritional supplement
DE10214005A1 (de)	2002-03-27	2003-10-09	Volker Bartz	Blutfettsenker zur oralen Einnahme, bestehend aus einem Gemisch aus den Omega-3-Fettsäuren EPA (Eicosapentaensäure) und DHA (Docosapentaensäure) und Pektin und/oder Guar als wirksame Substanzen, sowie gegebenenfalls zusätzlichen Stoffen wie antioxidative Vitamine, Aminosäuren und Spurenelemente
ITMI20020731A1 (it)	2002-04-08	2003-10-08	Ibsa Inst Biochimique Sa	Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3
NZ518504A (en)	2002-04-22	2005-05-27	Ind Res Ltd	Use of near-critical fluids in the separation of saturated and mono-unsaturated fatty acids from urea-containing solutions
SE0202188D0 (sv)	2002-07-11	2002-07-11	Pronova Biocare As	A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
EP2295529B2 (en)	2002-07-11	2022-05-18	Basf As	Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
NO319194B1 (no)	2002-11-14	2005-06-27	Pronova Biocare As	Lipase-katalysert forestringsfremgangsmate av marine oljer
US8017651B2 (en)	2002-11-22	2011-09-13	Bionexus, Ltd.	Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
AU2003288606A1 (en)	2002-12-20	2004-07-14	Pronova Biocare As	Use of a fatty acid composition for treatment of male infertility
US20070104856A1 (en)	2003-05-05	2007-05-10	Hakon Standal	Fish oils with an altered fatty acid profile, method of producing same and their use
US6846942B2 (en)	2003-05-20	2005-01-25	David Rubin	Method for preparing pure EPA and pure DHA
CA2531317A1 (en)	2003-07-09	2005-01-20	J-Oil Mills, Inc.	Antioxidant fat or oil composition containing long-chain highly unsaturated fatty acid
US7759507B2 (en)	2003-09-05	2010-07-20	Abbott Laboratories	Lipid system and methods of use
ITMI20032247A1 (it)	2003-11-19	2005-05-20	Tiberio Bruzzese	Interazione di derivati polari di composti insaturi con substrati inorganici
SE0303513D0 (sv)	2003-12-19	2003-12-19	Pronova Biocare As	Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
GB0403247D0 (en)	2004-02-13	2004-03-17	Tillotts Pharma Ag	A pharmaceutical composition
GB0413729D0 (en)	2004-06-18	2004-07-21	Tillotts Pharma Ag	A pharmaceutical composition and its use
GB0413730D0 (en)	2004-06-18	2004-07-21	Tillotts Pharma Ag	A pharmaceutical composition and its use
US20070265341A1 (en)	2004-07-01	2007-11-15	The Schepens Eye Research Institute Inc.	Compositions and methods for treating eye disorders and conditions
AU2005260232A1 (en)	2004-07-05	2006-01-12	Otago Innovation Limited	Hoki fish liver oil, fractions thereof and therapeutic uses
RU2388490C2 (ru)	2004-07-19	2010-05-10	Тиа Медика Ас	Композиция, содержащая растительный или рыбий жир, и соединения, содержащие неокисляющиеся структурные элементы жирных кислот
JP2008506774A (ja)	2004-07-19	2008-03-06	ティアメディカアクスイェセルスカプ	タンパク質材料と非酸化性脂肪酸体を含む組成物
WO2007130713A1 (en)	2006-02-01	2007-11-15	Transform Pharmaceuticals, Inc.	Novel fenofibrate formulations and related methods of treatment
WO2007130714A1 (en)	2006-02-01	2007-11-15	Transform Pharmaceuticals, Inc.	Novel statin pharmaceutical compositions and related methods of treatment
NZ552390A (en)	2004-08-06	2010-01-29	Transform Pharmaceuticals Inc	Novel fenofibrate formulations and related methods of treatment
JP2008509154A (ja) *	2004-08-06	2008-03-27	トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド	新規なスタチン薬剤組成物および関連治療方法
JP2008512490A (ja)	2004-09-08	2008-04-24	チェルシー・セラピューティクス，インコーポレイテッド	異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤
US20060067977A1 (en)	2004-09-28	2006-03-30	Atrium Medical Corporation	Pre-dried drug delivery coating for use with a stent
US20070191467A1 (en) *	2004-12-06	2007-08-16	Reliant Pharmaceutical, Inc.	Statin and omega-3 fatty acids for lipid therapy
DE102004062141A1 (de)	2004-12-23	2006-07-06	Nutrinova Nutrition Specialties & Food Ingredients Gmbh	Verfahren zur Herstellung eines Rohöls aus Gemischen von Mikroorganismen und Pflanzen, das so hergestellte Öl sowie die spezifischen Verwendungen des so hergestellten und gegebenenfalls zusätzlich raffinierten Öls
US20090054523A1 (en)	2005-01-24	2009-02-26	Morten Bryhn	Use of a Fatty Acid Composition Containing DHA for the Production of a Medical Product or a Food Stuff for the Treatment of Amyloidos-Related Diseases
US20080279935A1 (en)	2005-02-18	2008-11-13	Swg Invest As	Composition Comprising a Powder Containing Microencapsulated Polyunsaturated Long-Chain Esterified Fatty Acids Distributed in an Effervescent Base
KR20070108945A (ko)	2005-03-08	2007-11-13	릴라이언트 파마슈티컬스 인코퍼레이티드	스타틴과 오메가-3 지방산 및 그 조합물을 이용한 치료
DE102005013779A1 (de)	2005-03-22	2006-09-28	Basf Plant Science Gmbh	Verfahren zur Herstellung von mehrfach ungesättigten C20- und C22-Fettsäuren mit mindestens vier Doppelbindungen in transgenen Pflanzen
WO2006102896A2 (en)	2005-03-29	2006-10-05	Aalborg Universitet	A process to concentrate ω3-pufa from fish oil by selective hydrolysis using cutinase immobilized on zeolite nay
KR100539357B1 (ko)	2005-04-11	2005-12-28	동부한농화학 주식회사	불포화 지방산의 제조방법
WO2006117668A1 (en)	2005-05-04	2006-11-09	Pronova Biopharma Norge As	Fatty acid analogues, i.e. dha derivatives for uses as a medicament
US7485323B2 (en)	2005-05-31	2009-02-03	Gelita Ag	Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
AU2006265801B2 (en)	2005-07-01	2011-07-14	Martek Biosciences Corporation	Polyunsaturated fatty acid-containing oil product and uses and production thereof
US20070020340A1 (en)	2005-07-25	2007-01-25	David Rubin	Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension
MX2008001597A (es)	2005-08-04	2008-04-04	Transform Pharmaceuticals Inc	Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.
ITMI20051560A1 (it)	2005-08-10	2007-02-11	Tiberio Bruzzese	Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
US20070134493A1 (en)	2005-12-08	2007-06-14	Kanji Meghpara	Compositions and capsules with stable hydrophilic layers
NZ569068A (en)	2005-12-20	2011-11-25	Cenestra Llc	Omega 3 fatty acid formulations of EPA and DHA
FR2896172B1 (fr)	2006-01-17	2008-10-10	Polaris Soc Par Actions Simpli	Nouveau procede de stabilisation des acides gras polyinsatures et les compositions ainsi obtenus.
DE102006008030A1 (de)	2006-02-21	2007-08-23	Basf Plant Science Gmbh	Verfahren zur Herstellung von mehrfach ungesättigten Fettsäuren
AR059376A1 (es)	2006-02-21	2008-03-26	Basf Plant Science Gmbh	Procedimiento para la produccion de acidos grasos poliinsaturados
WO2007128801A1 (en)	2006-05-08	2007-11-15	Novartis Ag	Combination of organic compounds
US8003813B2 (en)	2006-06-27	2011-08-23	Pos Pilot Plant Corporation	Process for separating saturated and unsaturated fatty acids
KR100684641B1 (ko)	2006-07-25	2007-02-22	주식회사 일신웰스	유지 조성물, 이를 함유하는 식품 및 건강보조식품
WO2008012329A2 (en)	2006-07-28	2008-01-31	V. Mane Fils	Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
KR100758664B1 (ko)	2006-08-16	2007-09-13	(주)케비젠	불포화지방산 함유 마이크로캡슐의 제조방법, 이 방법에의해 제조된 마이크로캡슐 및 이를 포함하는 제품
CN101194913A (zh) *	2006-12-05	2008-06-11	张金生	治疗血脂偏高的天然海豹油浓缩生物制剂及其制备工艺
EP2124905B1 (en)	2007-01-10	2016-09-07	DSM Nutritional Products AG	Microcapsules including pea protein
JP2010515773A (ja)	2007-01-16	2010-05-13	リライアント・ファーマシューティカルズ・インコーポレイテッド	非ステロイド系抗炎症薬およびオメガ−３脂肪酸を用いる治療ならびにその組合せ生成物
WO2008103753A2 (en)	2007-02-20	2008-08-28	Martek Biosciences Corporation	Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
CA2677670C (en)	2007-03-20	2010-08-03	Centre De Recherche Sur Les Biotechnologies Marines	Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
CA2685272A1 (en)	2007-04-26	2008-11-06	Patrick Adlercreutz	A polyunsaturated fatty acid (pufa) enriched marine oil comprising eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), and a process of production thereof
WO2009009040A2 (en)	2007-07-06	2009-01-15	Baum Seth J	Fatty acid compositions and methods of use
CL2008002020A1 (es)	2007-07-12	2008-11-14	Ocean Nutrition Canada Ltd	Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite.
EP2173184A4 (en)	2007-07-25	2012-02-15	Epax As	OMEGA TYPE ENRICHED FATTY ACID COMPOSITION
US9556401B2 (en)	2007-07-30	2017-01-31	Nippon Suisan Kaisha, Ltd.	Method for producing EPA-enriched oil and DHA-enriched oil
WO2009020406A1 (en)	2007-08-07	2009-02-12	Granate Seed Limited	Methods of making lipid substances, lipid substances made thereby and uses thereof
WO2009028457A1 (ja)	2007-08-29	2009-03-05	Shinshu University	非アルコール性脂肪肝炎治療薬
DE102007055344A1 (de)	2007-11-19	2009-05-20	K. D. Pharma Bexbach Gmbh	Neue Verwendung von Omega-3-Fettsäure(n)
MX2010007609A (es)	2008-01-10	2010-08-04	Takeda Pharmaceutical	Formulacion de capsula.
US20090182049A1 (en)	2008-01-16	2009-07-16	Joar Arild Opheim	Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
EP2291499B1 (en)	2008-05-15	2020-02-12	Basf As	Krill oil process
WO2010028067A1 (en)	2008-09-02	2010-03-11	Amarin Corporation Plc	Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US20100062057A1 (en)	2008-09-10	2010-03-11	Pronova BioPharma Norge AS.	Formulation
DK2337857T3 (en)	2008-10-02	2017-05-22	Ramon Nieves Gonzalez	MICROALGE EXTRACT CONTAINING POLYUM Saturated W3 FAT ACIDS AND PROCEDURE FOR EXTRACING OIL FROM MICRO-ORGANISMS
JP6113954B2 (ja)	2008-10-31	2017-04-12	リピッドファーマシューティカルズイーエイチエフ．	医薬として使用するための脂肪酸
KR101383006B1 (ko)	2009-02-10	2014-04-08	아마린 파마, 인크.	고중성지방혈증 치료 방법
CN101822651A (zh) *	2009-03-05	2010-09-08	Dpa工业公司	可咀嚼胶囊及其制备方法
ES2894340T3 (es)	2009-03-09	2022-02-14	Basf As	Composiciones que comprenden una mezcla de aceites de ácidos grasos y un tensioactivo, y métodos y usos de las mismas
DK2429317T4 (da)	2009-04-17	2019-05-13	Natac Pharma S L	Sammensætninger med højt indhold af omega-3-fedtsyrer og med lavt indhold af phytansyre
PT3278665T (pt)	2009-04-29	2020-11-19	Amarin Pharmaceuticals Ie Ltd	Composição farmacêutica estável e métodos de utilização das mesmas
SG175390A1 (en)	2009-04-29	2011-12-29	Amarin Corp Plc	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
HRP20160598T4 (hr)	2009-05-01	2019-06-28	Uas Laboratories Llc	Bakterijski sastavi za prevenciju i liječenje degenerativne bolesti
CN106074486A (zh) *	2009-06-15	2016-11-09	阿马里纳药物爱尔兰有限公司	在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
WO2011028689A1 (en)	2009-09-01	2011-03-10	Catabasis Pharmaceuticals, Inc.	Fatty acid niacin conjugates and their uses
US20110071176A1 (en)	2009-09-23	2011-03-24	Amarin Pharma, Inc.	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US9370493B2 (en)	2009-10-23	2016-06-21	Pronova Biopharma Norge As	Coated capsules and tablets of a fatty acid oil mixture
RU2009145010A (ru)	2009-12-04	2011-06-20	Общество с ограниченной ответственностью (ООО) "Аббифарм" (RU)	Композиция омега-3 и омега-6 полиненасыщенных жирных кислот
WO2011095284A1 (de)	2010-02-02	2011-08-11	Cognis Ip Management Gmbh	Anreicherung von mehrfach ungesättigten fettsäuren
GB201006204D0 (en)	2010-04-14	2010-06-02	Ayanda As	Composition
WO2011133610A1 (en)	2010-04-22	2011-10-27	E. I. Du Pont De Nemours And Company	Method for obtaining polyunsaturated fatty acid-containing compositions from microbial biomass
US9476008B2 (en)	2010-06-25	2016-10-25	Epax As	Process for separating polyunsaturated fatty acids from long chain unsaturated or less saturated fatty acids
US20140004186A1 (en)	2010-09-08	2014-01-02	Pronova Biopharma Norge As	Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
US9145533B2 (en)	2010-09-24	2015-09-29	Pronova Blopharm Norge AS	Process for concentrating omega-3 fatty acids
WO2012083034A1 (en)	2010-12-15	2012-06-21	Louis Sanfilippo	Modulation of neurotrophic factors by omega-3 fatty acid formulations
WO2012087153A1 (en)	2010-12-23	2012-06-28	Marine Bioproducts As	Enrichment of marine oils with omega-3 polyunsaturated fatty acids by lipase-catalysed hydrolysis
EP2476425B1 (en)	2011-01-14	2014-03-19	Visiotact Pharma	Composition comprising OPC and Omega-3 for preventing and/or inhibiting the development of diabetic retinopathy
CA2827561A1 (en) *	2011-02-16	2012-08-23	Pivotal Therapeutics, Inc.	Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
WO2012112531A1 (en)	2011-02-16	2012-08-23	Pivotal Therapeutics, Inc.	Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
EP2675446A1 (en) *	2011-02-16	2013-12-25	Pivotal Therapeutics, Inc.	Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
EP2675444A1 (en)	2011-02-16	2013-12-25	Pivotal Therapeutics, Inc.	A formulations comprising omega 3 fatty acids and an anti obesity agent for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics
JP2014505729A (ja) *	2011-02-16	2014-03-06	ピヴォタルセラピューティクスインコーポレイテッド	コレステロールの低減および心血管事象の低減のための、コレステロール吸収阻害剤（アゼチジノン）およびω３脂肪酸（ＥＰＡ、ＤＨＡ、ＤＰＡ）
WO2012112902A1 (en)	2011-02-18	2012-08-23	Martek Biosciences Corporation	Methods of preparing free polyunsaturated fatty acids
US20140051877A1 (en)	2011-04-28	2014-02-20	Nandakishore Jeevanrao Duragkar	Eicosapentaenoic acid (epa) as polyunsaturated free fatty acid in its directly compressible powder form and process of isolation thereof
CN102311868B (zh)	2011-04-29	2017-05-24	塞拉斯有限责任公司	一种无溶剂提取富含磷脂和中性油脂的磷虾油的方法
US8697676B2 (en)	2011-06-15	2014-04-15	Ronald E Rosedale	Omega-3 fatty acid nutriceutical composition and optimization method
US20130095179A1 (en)	2011-09-15	2013-04-18	Omthera Pharmaceuticals, Inc.	Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
EP2806736A4 (en)	2011-10-21	2015-10-14	Omthera Pharmaceuticals Inc	METHODS AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF HYPERACTIVITY DISORDER WITH ATTENTION DEFICIT
US9861605B2 (en)	2011-10-24	2018-01-09	Stable Solutions Llc	Enriched injectable emulsion containing selected fatty acid triglycerides
RS57777B1 (sr)	2012-01-06	2018-12-31	Omthera Pharmaceuticals Inc	Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
JP6359517B2 (ja)	2012-03-30	2018-07-18	サンシリオアンドカンパニー, インコーポレイテッドSancilio & Company, Inc.	ω−３脂肪酸エステル組成物
EP2846779A4 (en)	2012-05-07	2015-12-16	Omthera Pharmaceuticals Inc	STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS
EP2861227A4 (en)	2012-06-17	2016-01-27	Matinas Biopharma Inc	OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
US20140194512A1 (en)	2012-06-17	2014-07-10	Matinas Biopharma, Inc.	Compositions comprising docosapentaenoic acid and methods of use
GB201216385D0 (en) *	2012-09-13	2012-10-31	Chrysalis Pharma Ag	A pharmaceutical composition
WO2016069446A1 (en)	2014-10-28	2016-05-06	Omthera Pharmaceuticals Inc	Methods for modulating plasma levels of lipoproteins
WO2016073335A1 (en)	2014-11-05	2016-05-12	Omthera Pharmaceuticals Inc.	Methods of treatment
WO2016130417A1 (en)	2015-02-11	2016-08-18	Omthera Pharmaceuticals Inc	Omega-3 fatty acid prodrug compounds and uses thereof
MA41611A (fr)	2015-02-23	2018-01-02	Omthera Pharmaceuticals Inc	Préparations en milli-capsules comprenant des acides gras polyinsaturés libres

2013
- 2013-01-04 RS RS20181033A patent/RS57777B1/sr unknown
- 2013-01-04 DK DK13733671.5T patent/DK2800563T3/en active
- 2013-01-04 PL PL13733671T patent/PL2800563T3/pl unknown
- 2013-01-04 EP EP18158463.2A patent/EP3348262A1/en not_active Withdrawn
- 2013-01-04 KR KR1020147021557A patent/KR102153143B1/ko not_active Expired - Fee Related
- 2013-01-04 UA UAA201407804A patent/UA114615C2/uk unknown
- 2013-01-04 HR HRP20181418TT patent/HRP20181418T1/hr unknown
- 2013-01-04 PE PE2014001081A patent/PE20142459A1/es active IP Right Grant
- 2013-01-04 HU HUE13733671A patent/HUE039659T2/hu unknown
- 2013-01-04 RU RU2018116572A patent/RU2018116572A/ru not_active Application Discontinuation
- 2013-01-04 US US14/370,730 patent/US20150004224A1/en not_active Abandoned
- 2013-01-04 CN CN201380012754.2A patent/CN104321055A/zh active Pending
- 2013-01-04 SM SM20180519T patent/SMT201800519T1/it unknown
- 2013-01-04 IN IN6125DEN2014 patent/IN2014DN06125A/en unknown
- 2013-01-04 NZ NZ626699A patent/NZ626699A/en not_active IP Right Cessation
- 2013-01-04 SG SG10201701004RA patent/SG10201701004RA/en unknown
- 2013-01-04 JP JP2014551376A patent/JP6399655B2/ja not_active Expired - Fee Related
- 2013-01-04 SG SG11201403805WA patent/SG11201403805WA/en unknown
- 2013-01-04 RU RU2014128500A patent/RU2664429C2/ru active
- 2013-01-04 MY MYPI2014002018A patent/MY165048A/en unknown
- 2013-01-04 MX MX2014008309A patent/MX358319B/es active IP Right Grant
- 2013-01-04 WO PCT/US2013/020398 patent/WO2013103902A1/en not_active Ceased
- 2013-01-04 LT LTEP13733671.5T patent/LT2800563T/lt unknown
- 2013-01-04 EP EP13733671.5A patent/EP2800563B1/en active Active
- 2013-01-04 CN CN201810809253.1A patent/CN108524483A/zh active Pending
- 2013-01-04 BR BR112014016788A patent/BR112014016788A8/pt not_active IP Right Cessation
- 2013-01-04 US US13/734,846 patent/US9050308B2/en not_active Expired - Fee Related
- 2013-01-04 CA CA2860512A patent/CA2860512C/en not_active Expired - Fee Related
- 2013-01-04 ES ES13733671.5T patent/ES2685703T3/es active Active
- 2013-01-04 CN CN201611034149.7A patent/CN107050457A/zh active Pending
- 2013-01-04 KR KR1020197029482A patent/KR102153245B1/ko not_active Expired - Fee Related
- 2013-01-04 PT PT13733671T patent/PT2800563T/pt unknown
- 2013-01-04 SI SI201331151T patent/SI2800563T1/sl unknown
- 2013-03-12 US US13/797,557 patent/US9050309B2/en not_active Expired - Fee Related
2014
- 2014-07-03 IL IL233517A patent/IL233517A/en active IP Right Grant
- 2014-07-04 PH PH12014501553A patent/PH12014501553A1/en unknown
- 2014-07-07 CL CL2014001803A patent/CL2014001803A1/es unknown
- 2014-07-07 DO DO2014000159A patent/DOP2014000159A/es unknown
- 2014-08-05 EC ECIEPI201412527A patent/ECSP14012527A/es unknown
- 2014-08-05 CO CO14170543A patent/CO7061070A2/es unknown
- 2014-08-05 ZA ZA2014/05765A patent/ZA201405765B/en unknown
2015
- 2015-03-17 HK HK18110835.8A patent/HK1251457A1/en unknown
- 2015-04-29 US US14/699,556 patent/US10117844B2/en not_active Expired - Fee Related
- 2015-10-06 PH PH12015502307A patent/PH12015502307B1/en unknown
2017
- 2017-05-03 IL IL252084A patent/IL252084B/en active IP Right Grant
- 2017-06-23 JP JP2017123521A patent/JP6626857B2/ja not_active Expired - Fee Related
2018
- 2018-09-06 CY CY181100930T patent/CY1120663T1/el unknown
- 2018-10-03 US US16/150,363 patent/US20190029985A1/en not_active Abandoned
2019
- 2019-04-24 IL IL266231A patent/IL266231B/en not_active IP Right Cessation
- 2019-11-29 JP JP2019217081A patent/JP2020045358A/ja not_active Ceased

Publication	Publication Date	Title
JP2015503590A5 (2)	2016-03-17
RU2018116572A (ru)	2018-10-23	Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA
HRP20210686T1 (hr)	2021-06-11	Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom
RU2017121277A (ru)	2018-12-19	Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения
NZ627238A (en)	2016-02-26	Stable pharmaceutical composition comprising ethyl eicosapentaenoate
JP2015143248A5 (2)	2015-12-24
JP6173437B2 (ja)	2017-08-02	スタチン及びω−３脂肪酸の組成物
HRP20210309T1 (hr)	2021-04-02	Postupci za smanjivanje rizika kardiovaskularnih slučajeva kod pojedinca na statinskoj terapiji uporabom etilestera eikosapentaenoične kiseline
JP2020128412A5 (2)	2022-07-20
JP2021534185A5 (2)	2022-08-22
RU2016129266A (ru)	2018-12-07	Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания
JP2013521310A5 (2)	2014-04-17
JP2020050675A (ja)	2020-04-02	認知機能改善および心拍数低下のための方法
RU2013154780A (ru)	2015-06-20	Способы лечения гипертриглицеридемии
JP2015503593A5 (2)	2016-02-12
NZ712068A (en)	2017-03-31	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2011097273A1 (en)	2011-08-11	Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine
JP2016501248A5 (2)	2017-01-26
US20140142127A1 (en)	2014-05-22	Stable Compositions of HMG-COA Reductase Inhibitors and Omega-3 Oils
AU2013201793B2 (en)	2015-03-19	DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
RU2014101714A (ru)	2015-07-27	Способ для снижения распространения инфекции у детей младшего возраста
HK1261434A1 (en)	2020-01-03	Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
AU2015203404A1 (en)	2015-07-16	DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
NZ807894B2 (en)	2025-12-02	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same